Insights
Newsletters
European Antitrust Bimonthly Bulletin – July/August 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
Newsletters
The Entrepreneurs Report – Q2 2026
Wilson Sonsini is pleased to present the Q2 2026 edition of The Entrepreneurs Report. We’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the second quarter, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital industry in general.
Newsletters
European Antitrust Bimonthly Bulletin – May/June 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
All Results
Client Highlights
9.14.26
Wilson Sonsini Advises Xapien on $56 Million Series B
On September 11, 2026, Xapien, an AI-native due diligence platform, announced a $56 million Series B investment round led by Spectrum Equity, with continued support from existing investor YFM Equity Partners. Wilson Sonsini Goodrich & Rosati advised Xapien on the transaction.
News Articles
9.14.26
Wilson Sonsini Attorneys Recognized in Lexology Index: Thought Leaders USA 2027
On September 9, 2026, nine Wilson Sonsini attorneys were named to the Lexology Index: Thought Leaders USA guide for 2027. The guide lists some of the U.S.'s foremost lawyers and experts in their respective fields. The following firm attorneys have been recognized in the guide:
Client Highlights
9.11.26
Firm Advises Frontier Computing on $10 Million Pre-Seed Round
On September 1, 2026, Frontier Computing announced that it has raised $10 million in a pre-seed round of financing. The round was led by General Catalyst, with participation from Amino Collective, LocalGlobe, Kaya, and Long Journey Ventures. Wilson Sonsini Goodrich & Rosati advised Frontier Computing on the transaction.
The UK-based start-up is growing the first biological brain systems at scale for machine learning training and inference workloads. Led by Cambridge natural scientist Michael Domarkas, the company says it has solved the vascularization problem that keeps academic brain organoids below 1 million neurons.
The Wilson Sonsini team that advised Frontier on the financing included Brad Doline, Michael Labriola, and Liam Holohan.
For more information, please see this article from Dealroom.co.
The UK-based start-up is growing the first biological brain systems at scale for machine learning training and inference workloads. Led by Cambridge natural scientist Michael Domarkas, the company says it has solved the vascularization problem that keeps academic brain organoids below 1 million neurons.
The Wilson Sonsini team that advised Frontier on the financing included Brad Doline, Michael Labriola, and Liam Holohan.
For more information, please see this article from Dealroom.co.
Client Highlights
9.11.26
Wilson Sonsini Advises GCVC Fund on Launch
On September 8, 2026, early-stage venture fund GCVC, backed by more than 50 sitting general counsels from prominent private and public companies, announced its launch. Wilson Sonsini Goodrich & Rosati is the first law firm to invest in the fund, and the firm’s Fund Services group, led by Brad Doline, represented GCVC in the transaction.
News Articles
9.11.26
Wilson Sonsini Attorneys Named Among 2027 Lawdragon 500 Leading Litigators in America
On September 11, 2026, Lawdragon named 33 Wilson Sonsini attorneys to its 2027 edition of Lawdragon 500 Leading Litigators in America. The lawyers featured in the guide represent the best litigators in the U.S. in antitrust, intellectual property, white collar and investigations, securities and corporate governance litigation, and a vast array of class actions, product liability, and other complex civil litigation.
Client Highlights
9.11.26
Wilson Sonsini Secures HKIAC Arbitration Final Award for Clients
On September 8, 2026, the Hong Kong International Arbitration Centre (HKIAC) issued a final award (the Final Award) in a dispute between Leed Education Holding Limited, National Education Holding Limited, and Hyde Education Holding Limited (collectively, the Claimants) and Minsheng Vocational Education Company Limited (the Respondent), a subsidiary of Hong Kong-listed Minsheng Education Group Company Limited (Minsheng Education). Wilson Sonsini Goodrich & Rosati acts for the Claimants in the arbitration.
News Articles
9.11.26
Wilson Sonsini, Wendy Devine Recognized During 2026 LMG Life Sciences Awards
Wilson Sonsini has been named “Hatch-Waxman Litigation Firm of the Year (Generic)” at the 2026 LMG Life Sciences Awards, an annual awards program that recognizes the leading law firms and attorneys to celebrate the successes in the life sciences industry. The firm was also named among the finalists for “Licensing and Collaboration Firm of the Year” and “Venture Capital Firm of the Year.”
Alerts
9.10.26
European Commission Adopts First Article 102 Guidelines on Exclusionary Abuses: Four Key Takeaways for Businesses
On September 3, 2026, the European Commission (EC) adopted its first Guidelines on the application of Article 102 of the Treaty on the Functioning of the European Union (TFEU) to exclusionary abuses of dominance (the Guidelines). The Guidelines provide a comprehensive framework for assessing dominance, exclusionary conduct, and objective justifications under European Union (EU) antitrust rules. The EC intends the Guidelines to increase legal certainty and help companies self-assess their conduct, while also providing a non-binding reference point for European national competition authorities and courts.1
Client Highlights
9.10.26
Wilson Sonsini Advises Autodesk on $1 Billion Senior Notes Offering
On September 10, 2026, Autodesk, Inc., completed its offering of $500 million aggregate principal amount of 5.050 percent senior notes due 2029 and $500 million aggregate principal amount of 5.650 percent senior notes due 2033 (together, the “Notes”). Autodesk intends to use the net proceeds from the sale of the Notes, together with cash on hand, to repay $1 billion aggregate principal amount under its existing term loan credit agreement. Wilson Sonsini Goodrich & Rosati advised Autodesk on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Copart on Acquisition of ACV
On September 10, 2026, Copart, Inc., a global leader in online vehicle auctions, and ACV, a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced a definitive agreement in which Copart will acquire all outstanding shares of ACV common stock, valued at approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Copart on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Fab2, Inc. on $500 Million Series A Financing at $3.7 Billion Valuation
On September 9, 2026, Fab2, Inc. (f/k/a Atomic Semi, Inc.) a semiconductor start-up that builds and mass-produces small chip fabs, announced the closing of a $500 million Series A financing led by Fundomo at a $3.7 billion valuation. Corner Capital, Paradigm, Duquesne Family Office, Maverick Silicon, StepStone Group, Protagonist, UDC Ventures, and angel investor Naval Ravikant also joined. Wilson Sonsini Goodrich & Rosati advised Fab2 on the transaction.
Client Highlights
9.10.26
Wilson Sonsini Advises Kura Oncology on Patent Matters Related to Launch of Caspian Therapeutics
On September 9, 2026, Kura Oncology (Kura), a biopharmaceutical company focused on precision medicines for the treatment of cancer, announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian was established around KO-7246, a next-generation, highly selective menin inhibitor purpose-designed for chronic metabolic diseases, together with related intellectual property and know-how contributed by Kura. Kura will retain approximately half ownership of Caspian and board representation. Caspian will operate with dedicated leadership and external capital with access to Kura’s research, development, and corporate capabilities under an intercompany services arrangement. Wilson Sonsini Goodrich & Rosati advised Kura on patent matters related to the transaction.